Rahul Saraogi shared his assessment of the macro backdrop for value investing in India at Asian Investing Summit 2017. He also shared his investment thesis on Jubilant Life Sciences (India: JOL).
According to Rahul, “India has cleaned up and consolidated its balance sheet. It has strong political leadership. Earnings growth has disappointed, but the outlook for earnings growth looks interesting. It looks like a coiled spring. Whether that spring will release this year or the following year is anybody’s guess, but it’s a good hunting ground. If there is a dip or a bigger debacle cost by an emerging markets crisis, that would be a buying opportunity in India.”
Rahul Saraogi leads Atyant Capital Advisors, advisor to the Atyant Capital India Fund. In the last 14 years he has focused on the Indian markets. His mission is to consistently identify the best 10-15 investment ideas from among the thousands of publicly-traded Indian corporations. Rahul’s value-based investment philosophy stands apart due to his belief in the paramount importance of corporate governance, specifically how management operates with its minority shareholders in mind. Prior to Atyant, Rahul Saraogi spent four years leading Meridian Investments, generating a 430% absolute return for the firm’s high net worth clients. He graduated from the Wharton School of the University of Pennsylvania with a degree in Economics. Outside of Atyant, he practices Vipassana, a 2,500 year-old meditation technique that helps people see things as they really are. Rahul Saraogi splits time between Chennai, India and Miami. You can read his latest thinking in the Atyant newsletter and blog, and connect with him on LinkedIn and Facebook.
Members, log in below to access the full session.
Not a member?
Thank you for your interest. Please note that MOI Global is closed to new members at this time. If you would like to join the waiting list, complete the following form: